KALV — Kalvista Pharmaceuticals Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Gold miners, Perpetua Resources, KalVista Pharmaceuticals
U.S. STOCKS ON THE MOVE-Gold miners, Perpetua Resources, KalVista Pharmaceuticals
KalVista Pharmaceuticals up after EU, Swiss approval for swelling disorder drug
Drug developer KalVista Pharmaceuticals posts Q1 revenue after new product launch
Brief: Kalvista Pharmaceuticals Announces Maintenance Of Orphan Designation For Sebetralstat In European Union
Brief: EMA's CHMP Recommended Not Granting A Marketing Authorisation For Elevidys For Treatment Of Duchenne Muscular Dystrophy
Brief: Kalvista Pharmaceuticals Announces UK MHRA Approval Of Ekterly (Sebetralstat)
KalVista Pharma ticks down after $100 mln stock offering filing
Kalvista Pharmaceuticals Inc reports results for the quarter ended April 30 - Earnings Summary
Brief: Kalvista Pharmaceuticals Inc - FDA Approves Kalvista's Ekterly For Hereditary Angioedema
Kalvista Pharmaceuticals Inc expected to post a loss of 86 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
U.S. STOCKS ON THE MOVE-U.S. Bancorp, IonQ, BlackRock
U.S. STOCKS ON THE MOVE- Cogent Biosciences, Sandstorm Gold, Tesla
U.S. STOCKS ON THE MOVE-Tesla, Constellation Brands, KalVista Pharma
Brief: KalVista Pharmaceuticals Announces FDA Approval of EKTERLY
KalVista Pharma rises as swelling disorder drug gets FDA approval
US FDA approves KalVista Pharma's swelling disorder drug (updated)
US FDA approves KalVista Pharma's swelling disorder drug